Cargando…

Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report

RATIONALE: Marfan syndrome is a rare cause of heart failure due to primary or secondary cardiomyopathy. Recently, sacubitril/valsartan—an angiotensin receptor blocker-neprilysin inhibitor—has been added in clinical practice as a standard therapy for heart failure. To our knowledge, there are no data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spoto, Silvia, Valeriani, Emanuele, Locorriere, Luciana, Anguissola, Giuseppina Beretta, Pantano, Angelo Lauria, Terracciani, Francesca, Bono, Maria Caterina, Costantino, Sebastiano, Ciccozzi, Massimo, Angeletti, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	3400
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882602/ https://www.ncbi.nlm.nih.gov/pubmed/31764806 http://dx.doi.org/10.1097/MD.0000000000017978

Ejemplares similares

Influenza B virus infection complicated by life-threatening pericarditis: a unique case-report and literature review
por: Spoto, Silvia, et al.
Publicado: (2019)

A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient
por: Spoto, Silvia, et al.
Publicado: (2020)

Diagnostic Accuracy and Prognostic Value of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Septic Patients outside the Intensive Care Unit
por: Spoto, Silvia, et al.
Publicado: (2021)

Active Surveillance Cultures and Procalcitonin in Combination With Clinical Data to Guide Empirical Antimicrobial Therapy in Hospitalized Medical Patients With Sepsis
por: Spoto, Silvia, et al.
Publicado: (2022)

Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis
por: Dai, Wenqin, et al.
Publicado: (2022)

Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study
por: Chen, Wenwen, et al.
Publicado: (2021)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial
por: Pang, Zhihua, et al.
Publicado: (2021)

Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article
por: Lin, Jiezhong, et al.
Publicado: (2021)

Visceral leishmaniasis triggering an adult‐onset Still's disease: a unique case
por: Spoto, Silvia, et al.
Publicado: (2017)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

High value of mid‐regional proadrenomedullin in COVID‐19: A marker of widespread endothelial damage, disease severity, and mortality
por: Spoto, Silvia, et al.
Publicado: (2021)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
por: Bonatto, Marcely Gimenes, et al.
Publicado: (2020)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
por: Ai, Jiao, et al.
Publicado: (2021)

Diffuse maculopapular rash: A family cluster during the last Chikungunya virus epidemic in Italy
por: Spoto, Silvia, et al.
Publicado: (2018)

A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy
por: De Vecchis, Renato, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis
por: Zhang, Weiliang, et al.
Publicado: (2017)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients
por: Yoo, Yung-Geun, et al.
Publicado: (2023)

Best diagnostic accuracy of sepsis combining SIRS criteria or qSOFA score with Procalcitonin and Mid-Regional pro-Adrenomedullin outside ICU
por: Spoto, Silvia, et al.
Publicado: (2020)

Treatment experience of thoracic aortic aneurysm recurrence after multiple surgeries for Marfan syndrome: A case report
por: Chen, Huai-Dong, et al.
Publicado: (2019)

Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
por: Spoto, Silvia, et al.
Publicado: (2022)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
por: Bell, Elisabeth, et al.
Publicado: (2022)

The role of procalcitonin in the diagnosis of bacterial infection after major abdominal surgery: Advantage from daily measurement
por: Spoto, Silvia, et al.
Publicado: (2018)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
por: Wu, Jiahui, et al.
Publicado: (2020)

Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials
por: De Vecchis, Renato, et al.
Publicado: (2019)

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
por: Vitale, Giuseppe, et al.
Publicado: (2019)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3qht50186t72klq2dl3v3ro9ta